XENON PHARMACEUTICALS INC. (XENE) Debt Components
- 2020-03-31: Long-term Debt, Current MaturitiesUSD $15.68M; Long-term Debt, Excluding Current MaturitiesUSD (m); Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2019-12-31: Long-term Debt, Current MaturitiesUSD $4.65M; Long-term Debt, Excluding Current MaturitiesUSD $10.89M; Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2019-12-31: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-Term Debt, Maturity, Year OneUSD $4.65M; Long-Term Debt, Maturity, Year TwoUSD $6.20M.
- 2019-09-30: Long-term Debt, Current MaturitiesUSD $3.62M; Long-term Debt, Excluding Current MaturitiesUSD $11.79M; Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD $5.17M.
XENON PHARMACEUTICALS INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-term Debt, Gross USD |
|---|---|---|---|---|---|---|---|---|---|
| 2020-03-31 | $15.68M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $4.65M | $10.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $4.65M | $6.20M | $4.65M | (m) | (m) | (m) | $15.50M |
| 2019-09-30 | $3.62M | $11.79M | (m) | $5.17M | $6.20M | $4.13M | (m) | (m) | $15.50M |
| 2019-06-30 | $2.07M | $13.20M | (m) | $5.17M | $6.20M | $4.13M | (m) | (m) | $15.50M |
| 2019-03-31 | (m) | $15.14M | (m) | $5.17M | $6.20M | $4.13M | (m) | (m) | $15.50M |
| 2018-12-31 | (m) | $15.01M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | $5.17M | $6.20M | $4.13M | (m) | (m) | $15.50M |
| 2018-09-30 | (m) | $14.89M | (m) | (m) | $5.17M | $6.20M | $4.13M | (m) | $15.50M |
| 2018-06-30 | (m) | $11.72M | (m) | (m) | $3.60M | $4.80M | $3.60M | (m) | $12.00M |
| 2018-03-31 | $1.40M | $5.48M | (m) | $2.80M | $2.80M | $700.00K | (m) | $700.00K | $7.00M |
| 2017-12-31 | $700.00K | $6.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $700.00K | $2.80M | $2.80M | $700.00K | (m) | (m) | $7.00M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |